1. South Korea Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Macrogen, Inc.

Macrogen, Inc.

KKRX:038290
11,160.00
KRW
+10.00
(+0.09%)
198.03EPS
45.22P/E
172.38BMarket Cap
Nov 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5,606.21
4,153.29
8,913.57
10,317.06
11,205.74
11,175.67
10,278.52
11,474.91
13,244.41
13,779.16
13,292.99
13,589.98
17,987.51
18,410.83
Basic EPS, GAAP
749.33
229.33
1,140
487
1,049
262
-350
9,002
114
-2,212
-1,683
-761
187
351.59
Free Cash Flow per Basic Share
719.45
-1,205.67
-294.42
720.81
156.17
783.37
-1,017.93
675.05
1,219.31
-896.31
-1,960.05
-2,838.88
-1,261.45
-858.41
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
300.15
294.69
301.29
299.44
300.32
0.72
Book Value per Share
6,854
7,582.35
8,625.45
9,296.04
10,360.24
11,778.44
11,480.44
20,306.42
20,289.99
17,860.8
15,952.48
14,834.18
14,505.29
14,017.46
Tangible Book Value per Share
6,844.47
7,564.36
8,560.35
9,241.24
10,284.76
11,691.04
10,571.29
20,180.85
20,161.88
17,643.58
15,689.33
11,119.11
10,972.74
10,509.54
Basic Weighted Avg Shares
9
13
9
9
9
10
10
10
10
10
10
10
11
11
Sales/Revenue/Turnover
48,078
54,130
79,534
91,113
101,793
112,831
102,815
112,603
129,175
138,617
132,803
135,777
195,268
199,599
Operating Margin (%)
7.42
4.8
5.24
3.45
2.97
0.82
3.62
6.36
9.13
3.82
-0.31
-4.59
0.09
1.36
Depreciation Expense
5,264
7,308
9,092
11,239
12,385
11,765
14,166
13,552
10,672
10,974
11,198
10,799
17,349
- -
Net Income, GAAP
6,426
2,989
10,172
4,301
9,529
2,645
-3,501
88,337
1,112
-22,253
-16,814
-7,603
2,030
3,812
Effective Tax Rate (%)
5.34
3.47
- -
22.06
20.6
15.55
- -
31.43
84.49
- -
- -
- -
- -
11.11
Profit Margin (%)
13.37
5.52
12.79
4.72
9.36
2.34
-3.41
78.45
0.86
-16.05
-12.66
-5.6
1.04
1.91
Working Capital
35,717
54,978
59,050
32,370
44,035
69,572
20,780
38,298
23,669
32,996
16,435
-13,996
-26,883
-35,425
LT Debt
188
29,358
29,452
9,067
10,311
- -
29,089
22,469
3,184
29,801
30,013
22,519
25,068
16,056
Total Equity
60,047
67,131
77,453
83,868
95,173
118,049
107,823
198,527
202,151
180,959
160,958
177,427
172,308
167,372
Return on Invested Capital (%)
4.95
3.02
- -
2.15
1.79
0.57
- -
2.54
0.77
- -
- -
- -
- -
0.94
Return on Capital (%)
11.4
3.86
- -
4.95
8.58
3.63
- -
45.82
0.02
- -
- -
- -
- -
2.13
Return on Common Equity (%)
11.56
4.72
14.23
5.42
10.78
2.49
-3.03
56.72
0.56
-11.71
-9.93
-4.75
1.28
2.48

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
56,582
76,469
84,094
LT Borrowings
32,146
16,361
16,056
LT Finance Leases
7,947
8,706
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
166,524
182,894
172,378

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
112,177
124,704
136,519
Cash, Cash Equivalents & STI
34,587
51,096
62,609
Accounts Receivable, Net
41,074
39,385
38,610
Inventories
28,164
24,986
27,644
Total Current Liabilities
130,782
151,587
171,943
Payables & Accruals
- -
- -
- -
ST Debt
56,582
76,469
84,094
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.89%
-2.47%
-2.89%
Free Cash Flow
-34.23%
2.8%
-51.72%
Net Income, GAAP
-527%
-481.21%
-126.7%
Sales/Revenue/Turnover
10.17%
12.78%
43.82%
Total Cash Common Dividend
- -
- -
8.98%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
31,640
30,163
33,003
40,971
135,777
2025
40,960
48,985
49,064
56,258
195,268
2026
45,292
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-216
-288
-319
59.76
-761
2025
-205
-146.38
226.69
311.61
187
2026
-40.33
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
299.44
2025
- -
- -
0.72
- -
300.32
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jeongsun Seo Changhoon Kim
Full Time Employees
488
Sector
Health services
Industry
Medical/Nursing services
Address
Seoul SL South Korea
IPO Date
Feb 22, 2000
Website
macrogen.com
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Mobile-health Network Solutions (NASDAQ:MNDR)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Macrogen, Inc. (038290.KQ) provides precision medicine and bio-engineering healthcare services focused on genomic analysis and bioinformatics in South Korea and internationally. Founded in 1997 and headquartered in Seoul, South Korea, the company offers personal healthcare services including disease prediction, wellness genetics, and direct-to-consumer genetic testing; MyPETGENE genetic testing for companion animals; clinical services such as precision medicine, cancer risk genetic testing, next-generation sequencing-based genetic panels, and good clinical laboratory practice services; single-cell expert services encompassing single-cell multi-omics, spatial transcriptome analysis, and in situ/spatial services; whole genome, whole exome, transcriptome, epigenome, and metagenome sequencing; standard sequencing, identification, fragment analysis, customized sequencing, and human identification services; expression, genome, and epigenome microarray; proteomics via Olink; gene synthesis; DNA and RNA oligonucleotide synthesis; peptide synthesis; and CRISPR knock-in/out, genome editing mouse, and mass production services. Macrogen operates through subsidiaries and branches including Psomagen Inc. in the United States, Macrogen Europe BV in the Netherlands, and facilities in Japan, Singapore, and Australia. Recent developments include an agreement on December 9, 2024, to acquire an additional 17.97% stake in Psomagen Inc. for KRW 14.23 billion; selection as final contractor in a consortium with DNA Link, Theragen Bio, and CG Invites for South Korea's National Integrated Bio Big Data Project to sequence and analyze 145,952 Korean genomes, announced December 23, 2024; and a November 18, 2024, service supply agreement with Samsung Electronics to integrate its GenTok digital healthcare platform, offering personalized genetic and microbiome-based wellness solutions including weight management, nutrition, and exercise recommendations via the Samsung Health app.